A Comparative Analysis of International Drug Price Negotiation Frameworks: An Interview Study of Key Stakeholders
High-income countries around the world adopt different approaches to conducting price negotiations on brand-name drugs but coalesce around a set of practices that will largely be absent from the current Medicare negotiation framework. US policymakers might consider adding some of these characteristics in the future to improve negotiation outcomes.
Authors
- William B. Feldman (ORCID: https://orcid.org/0000-0003-3467-5869)
- Aaron Seth Kesselheim (ORCID: https://orcid.org/0000-0002-8867-2666)
- Kevin Alan Schulman (ORCID: https://orcid.org/0000-0002-8926-5085)
- Iselin Dahlen Syversen
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Stanford University (US)
Publication Details
- Journal
- Milbank Quarterly
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1111/1468-0009.12714
- Citations
- 4
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 4.52
Funders
- Commonwealth Fund
- Brigham and Women's Hospital
- Arnold Ventures
- National Heart, Lung, and Blood Institute